Lv6
3130 积分 2022-10-27 加入
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
14小时前
已完结
Epidemiology of atopic dermatitis
4天前
已完结
Focused update: Guidelines of care for the management of atopic dermatitis in adults
10天前
已完结
Iptacopan: First Approval
1个月前
已完结
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria
1个月前
已完结
Factor B inhibition for paroxysmal nocturnal haemoglobinuria
1个月前
已完结
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
1个月前
已完结
Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan
1个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
1个月前
已完结
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
2个月前
已关闭
皖公网安备34019202002308
